Progranulin protein and FTLD

Recent data involving progranulin protein (PGRN) biology and frontotemporal lobar degeneration (FTLD), and the necessity of further elucidation of PGRN biology in FTLD-related neurodegeneration, is discussed by Nicholson and colleagues.

fMRI as an Alzheimer's disease biomarker

Vemuri and colleagues discuss the use of resting-state functional magnetic resonance imaging (fMRI) as an emerging Alzheimer's disease biomarker and consider future developments and open questions in the field.

Vascular risk factors and AD

Current studies fail to show a positive association between vascular risk factors and an increase in Alzheimer's disease (AD) pathology, as discussed in an evidence-based review by Chui and colleagues.

Patient self-report measures

The uses of, and issues associated with, patient-reported outcome measures in mild cognitive impairment and prodromal Alzheimer's disease are discussed by Frank and colleagues.

Molecular imaging progress in AD

Nordberg reviews recent progress in molecular imaging and functional biomarkers, which can provide valuable information for early Alzheimer's disease (AD) detection, assessing disease progression, and the development of new therapeutics.

Accurately predicting AD risk

In light of recent research, Barnes and Lee consider the current limitations and future directions in identifying individuals at increased risk of developing symptomatic Alzheimer's disease (AD).

Evaluating neuropsychological test results

Uniform Data Set clinical researchers are provided with a new online interactive calculator that provides a normative score to help evaluate neuropsychological test performance in subjects with Alzheimer's disease.